USTR Seeks Comments Questioning Foreign Nations' Interference With Drug Prices
The Office of the U.S. Trade Representative is seeking comments on whether any act, policy or practice relating to drug prices appears "unreasonable or discriminatory," or appears to have "the effect of forcing American patients to pay for a disproportionate amount of global pharmaceutical research and development, including by suppressing the price of pharmaceutical products below fair market value in foreign countries," it said in a Federal Register notice,
Sign up for a free preview to unlock the rest of this article
If your job depends on informed compliance, you need International Trade Today. Delivered every business day and available any time online, only International Trade Today helps you stay current on the increasingly complex international trade regulatory environment.
Comments are due by June 27, using docket number USTR-2025-0011, titled “Request for Comments Regarding Foreign Nations Freeloading on American-Financed Innovation.”
USTR said the request for comments is in response to President Donald Trump's executive order “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.”